WallStSmart

Eli Lilly and Company (LLY)vsJyong Biotech Ltd. Ordinary Shares (MENS)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

LLY leads profitability with a 31.9% profit margin vs 0.0%. LLY earns a higher WallStSmart Score of 74/100 (B).

LLY

Strong Buy

74

out of 100

Grade: B

Growth: 9.3Profit: 10.0Value: 5.0Quality: 6.0
Piotroski: 6/9Altman Z: 2.16

MENS

Avoid

17

out of 100

Grade: F

Growth: 4.3Profit: 3.5Value: 5.0Quality: 5.0
Piotroski: 5/9Altman Z: -4.07

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

LLY6 strengths · Avg: 9.7/10
Market CapQuality
$1.27T10/10

Mega-cap, among the largest globally

Return on EquityProfitability
68.5%10/10

Every $100 of equity generates 68 in profit

Profit MarginProfitability
31.9%10/10

Keeps 32 of every $100 in revenue as profit

Operating MarginProfitability
51.2%10/10

Strong operational efficiency at 51.2%

Revenue GrowthGrowth
38.6%10/10

Revenue surging 38.6% year-over-year

Free Cash FlowQuality
$8.22B8/10

Generating 8.2B in free cash flow

MENS1 strengths · Avg: 10.0/10
Debt/EquityHealth
-0.7410/10

Conservative balance sheet, low leverage

Areas to Watch

LLY3 concerns · Avg: 2.3/10
Debt/EquityHealth
1.233/10

Elevated debt levels

P/E RatioValuation
46.3x2/10

Premium valuation, high expectations priced in

Price/BookValuation
31.7x2/10

Trading at 31.7x book value

MENS4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$140.65M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
0.0%3/10

ROE of 0.0% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : LLY

The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 31.9% and operating margin at 51.2%. Revenue growth of 38.6% demonstrates continued momentum.

Bull Case : MENS

The strongest argument for MENS centers on Debt/Equity.

Bear Case : LLY

The primary concerns for LLY are Debt/Equity, P/E Ratio, Price/Book. A P/E of 46.3x leaves little room for execution misses.

Bear Case : MENS

The primary concerns for MENS are Revenue Growth, EPS Growth, Market Cap.

Key Dynamics to Monitor

LLY profiles as a growth stock while MENS is a value play — different risk/reward profiles.

LLY is growing revenue faster at 38.6% — sustainability is the question.

Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.

Bottom Line

LLY scores higher overall (74/100 vs 17/100), backed by strong 31.9% margins and 38.6% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Eli Lilly and Company

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.

Visit Website →

Jyong Biotech Ltd. Ordinary Shares

HEALTHCARE · BIOTECHNOLOGY · USA

Jyong Biotech Ltd. (ticker: MENS) is a pioneering biotechnology firm focused on developing transformative therapeutic solutions for cancer and autoimmune diseases. Leveraging its expertise in genomics and molecular biology, the company has built a promising pipeline of innovative treatments supported by a formidable intellectual property portfolio. By establishing strategic partnerships within the biopharmaceutical sphere, Jyong Biotech is well-positioned to capitalize on emerging market opportunities, all while emphasizing scientific excellence and a patient-centered approach that enhances its standing in the healthcare innovation arena.

Visit Website →

Want to dig deeper into these stocks?